1 week Ago By ABMN Staff
Chicago Capital LLC reduced its stake in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 0.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,689 shares of the company’s stock after selling 136 shares during the period.
Chicago Capital LLC’s holdings in Johnson & Johnson were worth $8,724,000 at the end of the most recent reporting period. A number of other institutional investors also recently bought and sold shares of JNJ. Citizens & Northern Corp increased its holdings in shares of Johnson & Johnson by 3.
5% in the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock worth $275,000 after buying an additional 63 shares during the last quarter. Carolinas Wealth Consulting LLC boosted its stake in shares of Johnson & Johnson by 0.
4% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after purchasing an additional 64 shares during the period. Epic Trust Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.
6% during the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock worth $268,000 after purchasing an additional 64 shares during the period. Verity Asset Management Inc.
boosted its stake in shares of Johnson & Johnson by 2.0% during the 4th quarter. Verity Asset Management Inc.
now owns 3,268 shares of the company’s stock worth $512,000 after purchasing an additional 65 shares during the period. Finally, Outfitter Financial LLC boosted its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter.
Outfitter Financial LLC now owns 16,632 shares of the company’s stock worth $2,431,000 after purchasing an additional 65 shares during the period. 69.55% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth JNJ has been the subject of a number of recent analyst reports. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.
00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $161.
00 to $171.00 in a research report on Thursday, July 18th. StockNews.
com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $167.00 to $169.
00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 3rd.
Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.
21. Insider Activity at Johnson & Johnson In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th.
The shares were sold at an average price of $165.06, for a total value of $930,113.10.
Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the SEC, which is available at this link .
0.16% of the stock is currently owned by corporate insiders. Johnson & Johnson Price Performance NYSE JNJ opened at $164.
38 on Monday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.
85. The firm’s 50 day moving average price is $157.57 and its 200-day moving average price is $153.
77. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.
85 and a current ratio of 1.07. The company has a market cap of $395.
61 billion, a PE ratio of 10.25, a P/E/G ratio of 2.73 and a beta of 0.
53. Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last posted its earnings results on Wednesday, July 17th. The company reported $2.
82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11.
Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%.
The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion.
During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 4.
3% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share.
The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.
02%. Johnson & Johnson’s payout ratio is 30.92%.
Johnson & Johnson Company Profile ( Free Report ) Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Featured Articles Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ). Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter .
.
